Concerns recently arose regarding hip resurfacing arthroplasty (HRA), mainly referring to the metal-on-metal articulation that results in increased metal ion concentrations and that may be associated with weird soft tissue reactions. Although a number of short-term reports highlighted excellent and encouraging outcomes after HRA, mid- to long-term follow-up studies are sparse in the current literature. This study aimed to determine the five-year results of HRA using the Durom® prosthesis in the first consecutive 50 cases. We prospectively assessed clinical and radiographic data for all patients undergoing HRA with this implant. Follow-ups were scheduled at six weeks, one year, two years and five years after surgery. All complications, revisions and failures were noted. Harris Hip Scores (HHS) and the range of motion (ROM) were determined preoperatively and at each follow-up. Oxford Hip Scores (OHS) and University of California at Los Angeles (UCLA) activity levels were determined at the last control. Comparisons were performed using paired t-tests after testing for normal distribution. The cohort comprised 13 women and 36 men (50 hips) with a mean age of 53.3 ± 10.7 years and a mean BMI of 25.9 ± 3.7 kg/m2. After a mean follow-up of 60.5 ± 2.3 months five hips had to be revised, corresponding to a resvision rate of 10%. There occurred two femoral neck fractures (after two and eleven months) and one aseptic loosening of the femoral component (after 68 months). One implant was exchanged to a conventional stem-type design due to persistent hip pain (after eight months), and one hip underwent a femoral offset correction due to a symptomatic impingement between the neck and the cup (after 29 months). There occurred no intra- or other postoperative complications. Clinically, ROM significantly improved after surgery. Hip flexion increased from 91.1 ± 15.8° to 98.9 ± 6.5° (p=0.0007), internal rotation from 5.5 ± 6.9° to 11.1 ± 8.1° (p=0.0005), external rotation from 19.2 ± 12.5° to 28.8 ± 9.1° (p=0.0001), and abduction from 27.3 ± 10.5° to 40.2 ± 11.0° (p<
0.0001). The HHS significantly increased from 55.9 ± 12.3 points to 96.5 ± 8.5 points. The OHS averaged 14.3 ± 3.0 points, and UCLA activity levels averaged 7.7 ± 1.7. The present results demonstrate that despite satisfactory clinical outcomes in terms of patient scores and ROM, the high revision rate of 10% after a mid-term follow-up is disappointing.